Valerie Morisset
Founder en ELIEM THERAPEUTICS, INC. .
Fortuna: 2 M $ al 30/04/2024
Origen de la red de primer grado Valerie Morisset.
| Entidad | Tipo de entidad | Industria | |
|---|---|---|---|
| Public Company | Biotechnology | 14 | |
Convergence Pharmaceuticals Ltd.
 Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom.
5
| Subsidiary | Pharmaceuticals: Major | 5 |
Eliem Therapeutics (UK) Ltd.
 Eliem Therapeutics (UK) Ltd. BiotechnologyHealth Technology Founded in 2019, Eliem Therapeutics (UK) Ltd. is a British company that engages in research and development on biotechnology. Part of Eliem Therapeutics, Inc., the private company is based in Altrincham, UK.
2
| Subsidiary | Biotechnology | 2 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a Valerie Morisset a través de su red personal
| Empresa | Sector | Personas relacionadas | Puesto principal |
|---|---|---|---|
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal General Counsel | |
| BIOGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Compliance Officer | |
| EXELIXIS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal General Counsel | |
Cavion, Inc.
 Cavion, Inc. Pharmaceuticals: MajorHealth Technology Cavion, Inc. engages in development of pharmaceuticals products. It produces oncology drugs to treat solid tumors that selectively inhibits the t-type calcium channel. The company was founded by Andrew J. Krouse, Lloyd S. Gray, and Timothy L. Macdonald in 2005 and is headquartered in Charlottesville, VA. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Arvinas Operations, Inc.
 Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | Biotechnology | Director/Board Member Director/Board Member | |
| ALZHEON, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
| University of Virginia | College/University | Graduate Degree Undergraduate Degree | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
| INTERMEDIATE CAPITAL GROUP PLC | Financial Conglomerates | Corporate Officer/Principal | |
| Clarkson University | College/University | Undergraduate Degree | |
| Lehigh University | College/University | Graduate Degree | |
| Yale University | College/University | Undergraduate Degree | |
GlaxoSmithKline, Inc.
 GlaxoSmithKline, Inc. Pharmaceuticals: MajorHealth Technology GlaxoSmithKline, Inc. manufactures and markets pharmaceutical products. The company develops medicines to prevent infections that cause serious medical problems such as respiratory illnesses, diabetes, viral control, infections, and central nervous system disorders. The company is headquartered in Mississauga, Canada. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| University of Michigan | College/University | Masters Business Admin Masters Business Admin | |
| University Of Dundee | College/University | Graduate Degree | |
| Wesleyan University | College/University | Doctorate Degree | |
Teva Pharmaceuticals USA, Inc.
 Teva Pharmaceuticals USA, Inc. Pharmaceuticals: MajorHealth Technology Teva Pharmaceuticals USA, Inc. engages in the manufacturing and marketing of generic pharmaceuticals. The firm also provides medical affairs, quality plus safety and trade partner services. The company was founded in 1985 and is headquartered in Parsippany, NJ. | Pharmaceuticals: Major | General Counsel | |
| GlaxoSmithKline (Pharmaceutical Operations) | Corporate Officer/Principal | ||
| ALDER BIOPHARMACEUTICALS, INC. | Pharmaceuticals: Major | General Counsel Chief Executive Officer Chief Operating Officer | |
| Humboldt-Universität zu Berlin | College/University | Doctorate Degree | |
| CLOVIS ONCOLOGY, INC. | Pharmaceuticals: Major | Director/Board Member | |
| Harvard Medical School | College/University | Doctorate Degree | |
Biogen Idec Ltd.
 Biogen Idec Ltd. BiotechnologyHealth Technology Biogen Idec Ltd. develops therapies for neurodegenerative, haematologic, and autoimmune disorders. The firm develops treatment for Alzheimer’s Disease, spinal muscular atrophy, lupus, and amyotrophic lateral sclerosis (ALS), amongst others. The company was founded on 2003 and is headquartered in Maidenhead, the United Kingdom. | Biotechnology | Director/Board Member Director/Board Member | |
Alliance for Regenerative Medicine
 Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Medical/Nursing Services | Director/Board Member | |
| University of Antwerp | College/University | Doctorate Degree | |
Clinton Health Access Initiative
 Clinton Health Access Initiative Miscellaneous Commercial ServicesCommercial Services The Clinton Health Access Initiative (CHAI) is a health organization that is dedicated to saving lives, reducing the burden of disease, and strengthening health systems. CHAI is based in Boston, MA, and the CEO of the non-profit company is Deepak Verma. The organization's focus is on improving healthcare in developing countries. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| Harvard Business School | College/University | Masters Business Admin | |
| JUNO THERAPEUTICS INC | Biotechnology | Corporate Officer/Principal | |
| ARVINAS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
| BRAEBURN INC. | Miscellaneous Commercial Services | General Counsel | |
Vitaeris, Inc.
 Vitaeris, Inc. BiotechnologyHealth Technology Vitaeris, Inc. develops new treatment options for chronic inflammatory diseases. The company was founded by Kevin Chow, Patrick A. Robinson and Noel F. Hall in 2016 and is headquartered in Vancouver, Canada. | Biotechnology | Director/Board Member | |
DomainTools LLC
 DomainTools LLC Packaged SoftwareTechnology Services DomainTools provides security system threat intelligence. Its products include IRIS investigation platform, phisheye, API integration, and personal domain research. The firm solutions include threat hunting, regulatory compliance, online fraud investigation, and phishing detection. The company is headquartered in Seattle, WA. | Packaged Software | Comptroller/Controller/Auditor | |
Silver Acquisition Co. Ltd.
 Silver Acquisition Co. Ltd. BiotechnologyHealth Technology Founded in 2014, Silver Acquisition Co. Ltd. is a biotechnology research and British experimental development company. Part of Biogen, Inc., the private company is based in Maidenhead, UK. The company's focus is on developing new biotechnology products through research and experimentation. | Biotechnology | Director/Board Member Director/Board Member | |
Convergence Pharmaceuticals Holdings Ltd.
 Convergence Pharmaceuticals Holdings Ltd. Financial ConglomeratesFinance Part of Biogen, Inc., Convergence Pharmaceuticals Holdings Ltd. functions as an investment holding British company. The private company is based in Maidenhead, UK. | Financial Conglomerates | Director/Board Member Director/Board Member | |
| NIGHTSTAR THERAPEUTICS PLC | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Imbria Pharmaceuticals, Inc.
 Imbria Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Imbria Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing novel therapies that restore cellular energy deficits. It focuses on restoring or improving the cell?s ability to produce energy where energy imbalances are at the root of disease, including cardiovascular diseases and inborn errors of metabolism. The company was founded by Andrew Levin and David-Alexandre C. Gros in 2018 and is headquartered in Boston, MA. | Pharmaceuticals: Major | Founder | |
Old Convergence Pharmaceuticals Ltd.
 Old Convergence Pharmaceuticals Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 2010, Old Convergence Pharmaceuticals Ltd. is a subsidiary of Biogen, Inc. that develops analgesics for the treatment of chronic pain. The private company is based in Maidenhead, UK. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Investment Managers | Private Equity Investor Private Equity Investor | |
Bridge Valley Ventures LLP
 Bridge Valley Ventures LLP Investment ManagersFinance Bridge Valley Ventures LLP is a Venture Capital firm founded in 2017. Bridge Valley Ventures LLP is headquartered in Cambridge. | Investment Managers | Private Equity Investor | |
| NEUROBO PHARMACEUTICALS, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
Lusaris Therapeutics, Inc.
 Lusaris Therapeutics, Inc. BiotechnologyHealth Technology Lusaris Therapeutics, Inc. is a biotechnology company that focuses on developing next-generation serotonergic neuroplastogen therapeutics to treat severe neuropsychiatric and neurological disorders. The company is based in Boston, MA. The company's lead program, LSR-1019, is a proprietary sublingual formulation of 5-MeO-DMT, a rapidly acting and rapidly clearing serotonergic psychedelic, which is being developed to treat treatment-resistant depression and other neuropsychiatric conditions. The company's pipeline also includes novel neuroplastogens for a wide range of neuropsychiatric and neurological conditions, including migraine and cluster headache. The CEO of the company is Andrew D. Levin. | Biotechnology | Chief Executive Officer | |
| Vzenium LLC | Founder | ||
Superluminal Medicines Inc
 Superluminal Medicines Inc BiotechnologyHealth Technology Superluminal Medicines Inc is a generative biological and chemical company. The company is based in Boston, MA. The CEO of the company is Cony D'Cruz. | Biotechnology | Director/Board Member |
Estadísticas
Internacional
| Estados Unidos | 36 |
| Reino Unido | 12 |
| Canadá | 3 |
| Alemania | 2 |
| Bélgica | 2 |
Sectorial
| Health Technology | 29 |
| Consumer Services | 12 |
| Finance | 5 |
| Commercial Services | 4 |
| Health Services | 2 |
Operativa
| Director/Board Member | 78 |
| Corporate Officer/Principal | 26 |
| Independent Dir/Board Member | 23 |
| Chief Executive Officer | 11 |
| General Counsel | 10 |
Las relaciones más conectadas
| Insiders | |
|---|---|
| Liam Ratcliffe | 32 |
| Andrew Levin | 21 |
| Robert Azelby | 15 |
| Leone Patterson | 14 |
| Adam Rosenberg | 13 |
| Trevor Anthony Mill | 10 |
| Simon Tate | 9 |
| Mark Versavel | 8 |
| Judith Dunn | 8 |
| James B. Bucher | 7 |
| Steven John Green | 7 |
| Erin Lavelle | 6 |
| Susan Franks | 5 |
| Joanne Palmer | 3 |
| Emily Pimblett | 3 |
- Bolsa de valores
- Insiders
- Valerie Morisset
- Conexiones Empresas
